Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Promedica Flower Hospital
mi
from
Sylvania, OH
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Promedica Flower Hospital
mi
from
Sylvania, OH
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
University Oncology Associates
mi
from
Clovis, CA
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
University Oncology Associates
mi
from
Clovis, CA
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
mi
from
Las Vegas, NV
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Ascension Providence Hospitals - Southfield
mi
from
Southfield, MI
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Ascension Providence Hospitals - Southfield
mi
from
Southfield, MI
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Cancer Care Specialists - Reno
mi
from
Reno, NV
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Cancer Care Specialists - Reno
mi
from
Reno, NV
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Minneapolis VA Medical Center
mi
from
Minneapolis, MN
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Minneapolis VA Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
James J Peters VA Medical Center
mi
from
Bronx, NY
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
James J Peters VA Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Community Cancer Institute
mi
from
Clovis, CA
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Community Cancer Institute
mi
from
Clovis, CA
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
AdventHealth Hendersonville
mi
from
Hendersonville, NC
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
AdventHealth Hendersonville
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
mi
from
Jonesboro, AR
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
NYP Weill Cornell Medical Center
mi
from
New York, NY
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
NYP Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Regional Cancer Center at Indian Path Community Hospital
mi
from
Kingsport, TN
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Regional Cancer Center at Indian Path Community Hospital
mi
from
Kingsport, TN
Click here to add this to my saved trials
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Click here to add this to my saved trials
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
West Palm Beach, FL
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Click here to add this to my saved trials
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Care Northwest
mi
from
Spokane, WA
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated:  12/31/1969
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated: 12/31/1969
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated:  12/31/1969
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated: 12/31/1969
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated:  12/31/1969
Lahey Clinic Medical Center - Burlington
mi
from
Burlington, MA
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated: 12/31/1969
Lahey Clinic Medical Center - Burlington
mi
from
Burlington, MA
Click here to add this to my saved trials
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated:  12/31/1969
Georgetown University Hospital
mi
from
Washington,
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated: 12/31/1969
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated:  12/31/1969
The Methodist Hospital for Liver Disease and Transplant
mi
from
Houston, TX
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Status: Enrolling
Updated: 12/31/1969
The Methodist Hospital for Liver Disease and Transplant
mi
from
Houston, TX
Click here to add this to my saved trials
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated:  12/31/1969
Tulane University Health Services Center
mi
from
New Orleans, LA
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated: 12/31/1969
Tulane University Health Services Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated:  12/31/1969
Virginia Mason Medical Center
mi
from
Seattle, WA
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated: 12/31/1969
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated:  12/31/1969
Seattle Cancer Care Alliance / University of Washington
mi
from
Seattle, WA
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated: 12/31/1969
Seattle Cancer Care Alliance / University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated:  12/31/1969
Cliniques Universitaires Saint-Luc
mi
from
Brussells,
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Status: Enrolling
Updated: 12/31/1969
Cliniques Universitaires Saint-Luc
mi
from
Brussells,
Click here to add this to my saved trials
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
A Phase II Trial of Erlotinib Plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Received First-line Sorafenib Therapy (AVF4572)
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
A Phase II Trial of Erlotinib Plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Received First-line Sorafenib Therapy (AVF4572)
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Phase II Study of Stereotactic Body Radiation Therapy (SBRT) After First-Line Chemotherapy for Metastatic NSCLC
Status: Enrolling
Updated:  12/31/1969
Coastal Carolina Radiation Oncology
mi
from
Wilmington, NC
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Phase II Study of Stereotactic Body Radiation Therapy (SBRT) After First-Line Chemotherapy for Metastatic NSCLC
Status: Enrolling
Updated: 12/31/1969
Coastal Carolina Radiation Oncology
mi
from
Wilmington, NC
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Phase II Study of Stereotactic Body Radiation Therapy (SBRT) After First-Line Chemotherapy for Metastatic NSCLC
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Phase II Study of Stereotactic Body Radiation Therapy (SBRT) After First-Line Chemotherapy for Metastatic NSCLC
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy
A Comparison of Methods for Assisting Needle Angle Selection During Image-Guided Tissue Biopsy
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy
A Comparison of Methods for Assisting Needle Angle Selection During Image-Guided Tissue Biopsy
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials